Indegene Ltd Share Price – NSE /  BSE

Healthcare, Small Cap

APL Apollo Tubes Ltd, Elgi Equipments Ltd, Kirloskar Oil Engines Ltd, AAVAS Financiers Ltd are among the other stocks to see a surge in volumes on BSE today, 12 February 2026.

Indegene Ltd registered volume of 5.38 lakh shares by 10:45 IST on BSE, a 38.48 fold spurt over two-week average daily volume of 13975 shares. The stock slipped 0.45% to Rs.471.05. Volumes stood at 10855 shares in the last session.

APL Apollo Tubes Ltd witnessed volume of 14.11 lakh shares by 10:45 IST on BSE, a 18.13 times surge over two-week average daily volume of 77831 shares. The stock dropped 0.04% to Rs.2,279.70. Volumes stood at 80089 shares in the last session.

Elgi Equipments Ltd notched up volume of 7.69 lakh shares by 10:45 IST on BSE, a 14.42 fold spurt over two-week average daily volume of 53332 shares. The stock rose 4.03% to Rs.516.50. Volumes stood at 18752 shares in the last session.

Kirloskar Oil Engines Ltd clocked volume of 1.87 lakh shares by 10:45 IST on BSE, a 9.43 times surge over two-week average daily volume of 19797 shares. The stock gained 5.25% to Rs.1,392.10. Volumes stood at 48933 shares in the last session.

AAVAS Financiers Ltd clocked volume of 99417 shares by 10:45 IST on BSE, a 8.94 times surge over two-week average daily volume of 11115 shares. The stock gained 0.79% to Rs.1,318.60. Volumes stood at 7842 shares in the last session.

Powered by Capital Market - Live News

Net profit of Indegene declined 6.20% to Rs 102.90 crore in the quarter ended December 2025 as against Rs 109.70 crore during the previous quarter ended December 2024. Sales rose 30.77% to Rs 942.10 crore in the quarter ended December 2025 as against Rs 720.40 crore during the previous quarter ended December 2024.

Powered by Capital Market - Live News

Indegene today announced that Jill DeSimone, a widely respected global life sciences leader, and Neeraj Bharadwaj, a renowned private equity leader, have joined Indegene's Board of Directors.

Jill brings over four decades of life sciences leadership, with hands-on experience building and leading large commercial and medical organizations. She has held senior leadership roles at leading biopharma companies, including President of U.S. Oncology at Merck, where she led major businesses and product franchises across global markets. She led the launch of Keytruda, Merck's first true oncology product. Jill has also held leadership roles at Teva and Bristol Myers Squibb. She currently serves on the Boards of several public and private biotech companies and brings a valuable set of experiences to Indegene.

Neeraj brings extensive experience in private equity, capital allocation, and portfolio value creation. He is currently a Senior Advisor with Carlyle Asia and previously held leadership roles at Accel Partners' growth investing operations in India and Apax Partners. He has worked closely with boards and management teams to support disciplined growth, inorganic expansion, and sustained value creation across scaled businesses, including healthcare and technology-enabled services.

Powered by Capital Market - Live News

Indegene will hold a meeting of the Board of Directors of the Company on 29 January 2026.

Powered by Capital Market - Live News